Goldman downgrades Watson Pharma

Goldman Sachs dealt a blow to Watson Pharmaceuticals today, downgrading the generics maker to "sell" and recommending that investors short the stock. A Goldman analyst cited the potential for lower sales of the iron-deficiency drug Ferrlecit and the company's intent to expand overseas. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.